Abstract:Background: Pathological cardiac fibrosis and hypertrophy, the common features of left ventricular remodeling, often progress to heart failure. Forkhead box transcription factor P1 (Foxp1) in endothelial cells (ECs) has been shown to play an important role in heart development. However, the effect of EC-Foxp1 on pathological cardiac remodeling has not been well clarified. This study aims to determine the role of EC-Foxp1 in pathological cardiac remodeling and the underlying mechanisms. Methods: Foxp1 EC-specific loss-of-function and gain-of-function mice were generated, and an angiotensin II infusion or a transverse aortic constriction operation mouse model was used to study the cardiac remodeling mechanisms. Foxp1 downstream target gene transforming growth factor-beta 1 (TGF-beta 1) was confirmed by chromatin immunoprecipitation and luciferase assays. Finally, the effects of TGF-beta 1 blockade on EC-Foxp1 deletion-mediated profibrotic and prohypertrophic phenotypic changes were further confirmed by pharmacological inhibition, more specifically by RGD-peptide magnetic nanoparticle target delivery of TGF-beta 1-siRNA to ECs. Results: Foxp1 expression is significantly downregulated in cardiac ECs during angiotensin II-induced cardiac remodeling. EC-Foxp1 deletion results in severe cardiac remodeling, including more cardiac fibrosis with myofibroblast formation and extracellular matrix protein production, as well as decompensated cardiac hypertrophy and further exacerbation of cardiac dysfunction on angiotensin II infusion or transverse aortic constriction operation. In contrast, EC-Foxp1 gain of function protects against pathological cardiac remodeling and improves cardiac dysfunction. TGF-beta 1 signals are identified as Foxp1 direct target genes, and EC-Foxp1 deletion upregulates TGF-beta 1 signals to promote myofibroblast formation through fibroblast proliferation and transformation, resulting in severe cardiac fibrosis. Moreover, EC-Foxp1 deletion enhances TGF-beta 1-promoted endothelin-1 expression, which significantly increases cardiomyocyte size and reactivates cardiac fetal genes, leading to pathological cardiac hypertrophy. Correspondingly, these EC-Foxp1 deletion-mediated profibrotic and prohypertrophic phenotypic changes and cardiac dysfunction are normalized by the blockade of TGF-beta 1 signals through pharmacological inhibition and RGD-peptide magnetic nanoparticle target delivery of TGF-beta 1-siRNA to ECs. Conclusions: EC-Foxp1 regulates the TGF-beta 1-endothelin-1 pathway to control pathological cardiac fibrosis and hypertrophy, resulting in cardiac dysfunction. Therefore, targeting the EC-Foxp1-TGF-beta 1-endothelin-1 pathway might provide a future novel therapy for heart failure.

Tumor Necrosis Factor-α-Induced C-C Motif Chemokine Ligand 20 Expression through TNF Receptor 1-Dependent Activation of EGFR/p38 MAPK and JNK1/2/FoxO1 or the NF-κB Pathway in Human Cardiac Fibroblasts

CCL24/CCR3 Axis Plays a Central Role in Angiotensin II–induced Heart Failure by Stimulating M2 Macrophage Polarization and Fibroblast Activation

Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1–Endothelin-1 Signal Pathway

Cytokine receptor-like factor 1 (CRLF1) promotes cardiac fibrosis via ERK1/2 signaling pathway

C-Reactive Protein Promotes Cardiac Inflammation and Fibrosis in Angiotensin Ii-Induced Hypertensive Cardiovascular Diseases

Tumor necrosis factor-α stimulation endothelial-to-mesenchymal transition during cardiac fibrosis via endothelin-1 signaling.

Tumor Necrosis Factor Induces Matrix Metalloproteinases in Cardiomyocytes and Cardiofibroblasts Differentially Via Superoxide Production in A Pi3k Gamma-Dependent Manner

Macrophage-derived CCL24 promotes fibrosis and worsens cardiac dysfunction during heart failure

Cardiomyocytes Overexpressing Tnf-Alpha Attract Migration Of Embryonic Stem Cells Via Activation Of P38 And C-Jun Amino-Terminal Kinase

CXCR 6 deficiency attenuates pressure overload-induced monocytes migration and cardiac fibrosis through downregulating TNF-α-dependent MMP 9 pathway

CGRP Derived from Cardiac Fibroblasts is an Endogenous Suppressor of Cardiac Fibrosis.

Hypoxia/ischemia Promotes CXCL10 Expression in Cardiac Microvascular Endothelial Cells by NFkB Activation.

CCL17 Aggravates Myocardial Injury by Suppressing Recruitment of Regulatory T Cells

TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation

Cardiac Β‐adrenergic Receptor Activation Mediates Distinct and Cell Type‐dependent Changes in the Expression and Distribution of Connexin 43

EGCG Inhibits CTGF Expression Via Blocking NF-κB Activation in Cardiac Fibroblast.

P2Y1 Receptor Agonist Attenuates Cardiac Fibroblasts Activation Triggered by TGF-1

E2F transcription factor 1 (E2F1) promotes the transforming growth factor TGF-β1 induced human cardiac fibroblasts differentiation through promoting the transcription of CCNE2 gene

The CXCL10/CXCR3 Axis Promotes Cardiac Microvascular Endothelial Cell Migration Via the P38/fak Pathway in a Proliferation-Independent Manner.

Transmembrane tumor necrosis factor alpha attenuates pressure-overload cardiac hypertrophy via tumor necrosis factor receptor 2

P2Y1 Receptor Agonist Attenuates Cardiac Fibroblasts Activation Triggered by TGF-β1